Research progress of vascular endothelial growth factor inhibitor in the treatment of corneal neovascularization

Authors:Lin Tianlan,  Zhou Shanbi
DOI: 10.3760/cma.j.issn.2095-0160.2016.04.018
Published 2016-04-10
Cite as Chin J Exp Ophthalmol, 2016,34(4): 371-374.

Abstract

Normal cornea is avascular, fully transparent organization, which is important to the eye refraction.However, many eye diseases can destroy the anti-angiogenic factor and pro-angiogenic factors balance, resulting in pathological corneal neovascularization (CNV) formation.Numerous studies show that activation of signaling pathways are closely related to CNV formation and vascular endothelial growth factor (VEGF). Multiple targets and multi-channel blocker can effectively inhibit the signaling pathway of angiogenesis, which brought hope for the treatment of CNV.Currently new targeted treatment strategy to ocular neovascularization include VEGF inhibitors and with the core of miRNA gene therapy.The former mainly include anti-VEGF monoclonal antibodies, aptamers, VEGF trap, VEGF receptor (VEGFR) tyrosine kinase inhibitor, etc.This article reviewed the mechanism of action, drug efficacy, drug safety and research status of representative anti-VEGF drugs and Gene therapy.

Key words:

Corneal neovascularization; Vascular endothelial growth factor; Molecular targeted therapy; MicroRNA

Contributor Information

Lin Tianlan
Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Zhou Shanbi
(Read 75 times, 1 visits today)
Updated: October 9, 2019 — 4:08 am